Kim R Tsuchimoto is Chief Financial Officer of Monopar Therapeutics. Currently has a direct ownership of 57,429 shares of MNPR, which is worth approximately $1.43 Million. The most recent transaction as insider was on Jun 30, 2024, when has been sold 2,998 shares (Common Stock) at a price of $0.73 per share, resulting in proceeds of $2,188. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 57.4K
0% 3M change
51.18% 12M change
Total Value Held $1.43 Million

Kim R Tsuchimoto Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 30 2024
SELL
Payment of exercise price or tax liability
$2,188 $0.73 p/Share
2,998 Reduced 4.96%
57,429 Common Stock
Jun 30 2024
BUY
Exercise of conversion of derivative security
-
9,957 Added 14.15%
60,427 Common Stock
Mar 31 2024
SELL
Payment of exercise price or tax liability
$2,775 $0.68 p/Share
4,082 Reduced 7.48%
50,470 Common Stock
Mar 31 2024
BUY
Exercise of conversion of derivative security
-
9,956 Added 15.43%
54,552 Common Stock
Jan 01 2024
SELL
Payment of exercise price or tax liability
$171 $0.34 p/Share
505 Reduced 1.12%
44,596 Common Stock
Jan 01 2024
BUY
Exercise of conversion of derivative security
-
1,231 Added 2.66%
45,101 Common Stock
Dec 31 2023
SELL
Payment of exercise price or tax liability
$1,384 $0.34 p/Share
4,073 Reduced 8.5%
43,870 Common Stock
Dec 31 2023
BUY
Exercise of conversion of derivative security
-
9,957 Added 17.2%
47,943 Common Stock
Sep 30 2023
SELL
Payment of exercise price or tax liability
$2,135 $0.62 p/Share
3,444 Reduced 8.31%
37,986 Common Stock
Sep 30 2023
BUY
Exercise of conversion of derivative security
-
9,956 Added 19.37%
41,430 Common Stock
Jun 30 2023
SELL
Payment of exercise price or tax liability
$4,389 $0.86 p/Share
5,104 Reduced 13.95%
31,474 Common Stock
Jun 30 2023
BUY
Exercise of conversion of derivative security
-
14,846 Added 28.87%
36,578 Common Stock
Mar 31 2023
SELL
Payment of exercise price or tax liability
$2,560 $1.39 p/Share
1,842 Reduced 7.81%
21,732 Common Stock
Mar 31 2023
BUY
Exercise of conversion of derivative security
-
5,067 Added 17.69%
23,574 Common Stock
Jan 01 2023
SELL
Payment of exercise price or tax liability
$1,189 $2.37 p/Share
502 Reduced 2.64%
18,507 Common Stock
Jan 01 2023
BUY
Exercise of conversion of derivative security
-
1,230 Added 6.08%
19,009 Common Stock
Dec 31 2022
SELL
Payment of exercise price or tax liability
$4,898 $2.37 p/Share
2,067 Reduced 10.42%
17,779 Common Stock
Dec 31 2022
BUY
Exercise of conversion of derivative security
-
5,067 Added 20.34%
19,846 Common Stock
Sep 30 2022
SELL
Payment of exercise price or tax liability
$2,665 $1.52 p/Share
1,753 Reduced 10.6%
14,779 Common Stock
Sep 30 2022
BUY
Exercise of conversion of derivative security
-
5,066 Added 23.46%
16,532 Common Stock
Jun 30 2022
SELL
Payment of exercise price or tax liability
$7,091 $2.3 p/Share
3,083 Reduced 21.19%
11,466 Common Stock
Jun 30 2022
BUY
Exercise of conversion of derivative security
-
8,913 Added 37.99%
14,549 Common Stock
Mar 31 2022
SELL
Payment of exercise price or tax liability
$1,275 $2.55 p/Share
500 Reduced 8.15%
5,636 Common Stock
Mar 31 2022
BUY
Exercise of conversion of derivative security
-
1,221 Added 16.6%
6,136 Common Stock
Jan 01 2022
SELL
Payment of exercise price or tax liability
$1,621 $3.21 p/Share
505 Reduced 9.32%
4,915 Common Stock
KRT

Kim R Tsuchimoto

Chief Financial Officer
Wilmette, IL

Track Institutional and Insider Activities on MNPR

Follow Monopar Therapeutics and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MNPR shares.

Notify only if

Insider Trading

Get notified when an Monopar Therapeutics insider buys or sells MNPR shares.

Notify only if

News

Receive news related to Monopar Therapeutics

Track Activities on MNPR